A share price of Zentalis Pharmaceuticals Inc [ZNTL] is currently trading at $1.52, up 3.40%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ZNTL shares have gain 25.62% over the last week, with a monthly amount glided 23.58%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Zentalis Pharmaceuticals Inc [NASDAQ: ZNTL] stock has seen the most recent analyst activity on August 12, 2024, when Wedbush upgraded its rating to a Neutral but kept the price target unchanged to $4 for it. Previously, UBS downgraded its rating to Neutral on June 20, 2024, and dropped its price target to $5. On June 18, 2024, downgrade downgraded it’s rating to Equal Weight. Wedbush downgraded its rating to a Underperform and decreased its price target to $4 on June 18, 2024. Morgan Stanley downgraded its rating to a Equal-Weight and reduced its price target to $8 on June 18, 2024. Jefferies downgraded its rating to Hold for this stock on June 18, 2024, and downed its price target to $6. In a note dated November 08, 2023, Wedbush downgraded an Neutral rating on this stock and revised its target price from $38 to $12.
Zentalis Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $1.01 and $11.91. Currently, Wall Street analysts expect the stock to reach $21.86 within the next 12 months. Zentalis Pharmaceuticals Inc [NASDAQ: ZNTL] shares were valued at $1.52 at the most recent close of the market. An investor can expect a potential return of 1338.16% based on the average ZNTL price forecast.
Analyzing the ZNTL fundamentals
Trailing Twelve Months sales for Zentalis Pharmaceuticals Inc [NASDAQ:ZNTL] were 26.86M which represents -100.00% decline. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -7.89%, Pretax Profit Margin comes in at -8.34%, and Net Profit Margin reading is -8.34%. To continue investigating profitability, this company’s Return on Assets is posted at -0.58, Equity is -0.65 and Total Capital is -0.63. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.4600 points at the first support level, and at 1.4000 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.5700, and for the 2nd resistance point, it is at 1.6200.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Zentalis Pharmaceuticals Inc [NASDAQ:ZNTL] is 6.94. Also, the Quick Ratio is 6.94, while the Cash Ratio stands at 0.85. Considering the valuation of this stock, the price to sales ratio is 4.07, the price to book ratio is 0.37.
Transactions by insiders
Recent insider trading involved Myers Scott Dunseth, Director, that happened on Apr 30 ’25 when 21000.0 shares were purchased. Chief Medical Officer, Bruns Ingmar completed a deal on Feb 06 ’25 to buy 20000.0 shares. Meanwhile, Former Director Cam Gallagher bought 687.0 shares on Feb 11 ’25.
